HCW Biologics Balance Sheet Health
Financial Health criteria checks 4/6
HCW Biologics has a total shareholder equity of $13.5M and total debt of $6.4M, which brings its debt-to-equity ratio to 47.7%. Its total assets and total liabilities are $28.5M and $15.1M respectively.
Key information
47.7%
Debt to equity ratio
US$6.42m
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.60m |
| Equity | US$13.46m |
| Total liabilities | US$15.05m |
| Total assets | US$28.51m |
Financial Position Analysis
Short Term Liabilities: HCWB's short term assets ($6.4M) do not cover its short term liabilities ($8.7M).
Long Term Liabilities: HCWB's short term assets ($6.4M) exceed its long term liabilities ($6.3M).
Debt to Equity History and Analysis
Debt Level: HCWB's net debt to equity ratio (21%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if HCWB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HCWB has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: HCWB is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.